Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Sarcoma × anlotinib × Clear all

Phase

Phase 2 8 Phase 1/2 2 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 1 Sarcoma 1 Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Differentiated Thyroid Cancer 1 Carcinoma, Medullary 1 Biliary Tract Neoplasms 1 Advanced Solid Tumor 1

Interventions

Doxorubicin 3 Radiotherapy 2 Drug Therapy 2 pirarubicin 1 pazopanib 1 liposomal doxorubicin 1 anlotinib 1 Triptorelin Pamoate 1 Trabectedin 1 Radiation 1 Methotrexate 1 Ifosfamide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡